NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

Thank you for sharing your critical thinking.

I don't know the answer to my questions. As a matter of fact, I have more questions.

Was the analysis as mentioned in the unpublished paper carried out before the re-ignition of the Moonshot program?
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE249282
https://www.whitehouse.gov/briefing-room/statements-releases/2022/02/02/fact-sheet-president-biden-reignites-cancer-moonshot-to-end-cancer-as-we-know-it/
I have no affirmative answer. Based on the words in 10Q from August 2020, it could be

As the Company recently reported, this process has been completed and all of the trial sites are now finished. The data from the trial sites comprises most, though not all, of the data required for analyzing the trial. The remaining required data includes information from specialized vendors -- for example, genetic profiles such as IDH mutations. When this external data joins the now locked data from the trial sites, the overall trial dataset will be locked.

Was the following part from Dr. Monica Bertagnoli's NCI report related to the combo trial? I did some investigations. I don't have affirmative answer either.

In 2021, NCI launched the Glioblastoma Therapeutics Network (GTN), a national multi-institutional collaborative effort with the goal of taking novel therapeutic agents from preclinical studies in models of GBM into pilot clinical studies that include biomarkers of effects.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172924113

In March 2020, around the same time the combo trial was underway, NIH placed orders to several companies including Albany Molecular Research INC (currently Curia Global) which has employees listed as inventors of the new poly-iclc patent, CRL which provided DCVax vaccine for the clinical trial before, and others. The one to Rutgers State University was about genetic studies. The one to The Emmes Company LLC was about statistics and clinical trial support center management and support. Are these grants related to the combo trial? The timing is interesting. We cannot rule out the possibility.



Did you see the linkedin post from Oncovir? People from Curia Global liked the post. Does Curia Global have close connection with Oncovir? Maybe.

So more questions and no definitive answers. We can only guess, which is fun.